Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Condition: Hormone Sensitive Prostate Cancer · Prostate Cancer · Cancer of the Prostate · Sponsor: Pfizer
About this study
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (255)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of Alabama at Birmingham, IDS Pharmacy | Birmingham, Alabama, United States | — |
| Alaska Urological Institute dba Alaska Clinical Research Center | Anchorage, Alaska, United States | — |
| Arizona Urology Specialists | Tucson, Arizona, United States | — |
| Tower Hematology Oncology Medical Group | Beverly Hills, California, United States | — |
| Cedars-Senai OCC Pharmacy | Los Angeles, California, United States | — |
| Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles, California, United States | — |
| University of California, Irvine Medical Center | Orange, California, United States | — |
| Sutter Medical Group, Vascular & Varicose Vein Center | Roseville, California, United States | — |
| Sutter Medical Group | Roseville, California, United States | — |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
+ 243 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02319837